These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 32719733)

  • 1. Informing iQOS Regulations in the United States: A Synthesis of What We Know.
    Berg CJ; Bar-Zeev Y; Levine H
    Sage Open; 2020; 10(1):. PubMed ID: 32719733
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FDA's reduced exposure marketing order for IQOS: why it is not a reliable global model.
    Lempert LK; Bialous S; Glantz S
    Tob Control; 2022 Aug; 31(e1):e83-e87. PubMed ID: 33811155
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Heated tobacco products likely appeal to adolescents and young adults.
    McKelvey K; Popova L; Kim M; Chaffee BW; Vijayaraghavan M; Ling P; Halpern-Felsher B
    Tob Control; 2018 Nov; 27(Suppl 1):s41-s47. PubMed ID: 30352843
    [TBL] [Abstract][Full Text] [Related]  

  • 4. IQOS: examination of Philip Morris International's claim of reduced exposure.
    St Helen G; Jacob Iii P; Nardone N; Benowitz NL
    Tob Control; 2018 Nov; 27(Suppl 1):s30-s36. PubMed ID: 30158205
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Industry marketing of tobacco products on social media: case study of Philip Morris International's IQOS.
    Abroms LC; Wysota CN; Tosakoon S; Khayat A; Duan Z; Bar-Zeev Y; Berg CJ; Levine H
    Tob Control; 2024 Jun; 33(4):518-524. PubMed ID: 36927516
    [TBL] [Abstract][Full Text] [Related]  

  • 6. United States Food and Drug Administration's authorization of reduced exposure claims for IQOS
    Eckford R; Severini G; Sebrié EM; Muggli ME; Beem A; Rosen D; Crosbie E
    Rev Panam Salud Publica; 2022; 46():e155. PubMed ID: 36245905
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessment of industry data on pulmonary and immunosuppressive effects of IQOS.
    Moazed F; Chun L; Matthay MA; Calfee CS; Gotts J
    Tob Control; 2018 Nov; 27(Suppl 1):s20-s25. PubMed ID: 30158203
    [TBL] [Abstract][Full Text] [Related]  

  • 8. IQOS point-of-sale marketing: a comparison between Arab and Jewish neighborhoods in Israel.
    Khayat A; Levine H; Berg CJ; Abroms LC; Duan Z; Wang Y; LoParco CR; Elbaz D; Cui Y; Bar-Zeev Y
    Isr J Health Policy Res; 2024 Aug; 13(1):39. PubMed ID: 39152466
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Creating a market for IQOS: analysis of Philip Morris' strategy to introduce heated tobacco products to the Australian consumer market.
    Watts C; Burton S; Freeman B
    Tob Control; 2022 May; 31(3):458-463. PubMed ID: 33191270
    [TBL] [Abstract][Full Text] [Related]  

  • 10. How Media Stories in Low- and Middle-Income Countries Discussed the U.S. Food and Drug Administration's Modified Risk Tobacco Product Order for IQOS.
    Robichaud MO; Puryear T; Cohen JE; Kennedy RD
    Nicotine Tob Res; 2023 Aug; 25(10):1659-1666. PubMed ID: 37310968
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modelling the impact of a new tobacco product: review of Philip Morris International's Population Health Impact Model as applied to the IQOS heated tobacco product.
    Max WB; Sung HY; Lightwood J; Wang Y; Yao T
    Tob Control; 2018 Nov; 27(Suppl 1):s82-s86. PubMed ID: 30275170
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Heated tobacco product regulation under US law and the FCTC.
    Lempert LK; Glantz SA
    Tob Control; 2018 Nov; 27(Suppl 1):s118-s125. PubMed ID: 30291201
    [TBL] [Abstract][Full Text] [Related]  

  • 13. IQOS labelling will mislead consumers.
    McKelvey K; Popova L; Kim M; Lempert LK; Chaffee BW; Vijayaraghavan M; Ling P; Halpern-Felsher B
    Tob Control; 2018 Nov; 27(Suppl 1):s48-s54. PubMed ID: 30158208
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Revolution or redux? Assessing IQOS through a precursor product.
    Elias J; Dutra LM; St Helen G; Ling PM
    Tob Control; 2018 Nov; 27(Suppl 1):s102-s110. PubMed ID: 30305324
    [TBL] [Abstract][Full Text] [Related]  

  • 15. IQOS print magazine advertising characteristics and reach before and after FDA authorisation as a modified risk tobacco product.
    Ganz O; Strasser AA; Giovenco DP; Audrain-McGovern J; Cappella JN; Safi Z; Tan ASL; Talbot EM; Delnevo CD
    Tob Control; 2024 Sep; 33(5):680-683. PubMed ID: 36958825
    [TBL] [Abstract][Full Text] [Related]  

  • 16. IQOS Marketing Strategies and Expenditures in the United States From Market Entrance in 2019 to Withdrawal in 2021.
    Duan Z; Levine H; Romm KF; Bar-Zeev Y; Abroms LC; Griffith L; Wang Y; Khayat A; Cui Y; Berg CJ
    Nicotine Tob Res; 2023 Sep; 25(11):1798-1803. PubMed ID: 37338204
    [TBL] [Abstract][Full Text] [Related]  

  • 17. IQOS point-of-sale marketing: a comparison between Arab and Jewish neighborhoods in Israel.
    Khayat A; Levine H; Berg CJ; Abroms LC; Duan Z; Wang Y; LoParco CR; Elbaz D; Cui Y; Bar-Zeev Y
    Res Sq; 2024 Mar; ():. PubMed ID: 38464035
    [TBL] [Abstract][Full Text] [Related]  

  • 18. IQOS point-of-sale marketing strategies in Israel: a pilot study.
    Bar-Zeev Y; Levine H; Rubinstein G; Khateb I; Berg CJ
    Isr J Health Policy Res; 2019 Jan; 8(1):11. PubMed ID: 30642383
    [TBL] [Abstract][Full Text] [Related]  

  • 19. IQOS Marketing in the US: The Need to Study the Impact of FDA Modified Exposure Authorization, Marketing Distribution Channels, and Potential Targeting of Consumers.
    Berg CJ; Abroms LC; Levine H; Romm KF; Khayat A; Wysota CN; Duan Z; Bar-Zeev Y
    Int J Environ Res Public Health; 2021 Oct; 18(19):. PubMed ID: 34639851
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of IQOS introduction on Philip Morris International cigarette sales in Spain: a Logarithmic Mean Divisa Index decomposition approach.
    Golpe AA; Martín-Álvarez JM; Galiano A; Asensio E
    Gac Sanit; 2022; 36(4):293-300. PubMed ID: 35219532
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.